New drug strategy aims to boost immune attack on lung cancer before and after surgery
NCT ID NCT05206812
Summary
This study is testing if giving an immunotherapy drug called durvalumab before and after surgery helps control non-small cell lung cancer. It involves 25 people with operable cancer. The main goal is to see how much the drug shrinks the tumor before it's removed and to understand how the body's immune system responds to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.